[go: up one dir, main page]

JPS56128721A - Antiallergic agent - Google Patents

Antiallergic agent

Info

Publication number
JPS56128721A
JPS56128721A JP3030880A JP3030880A JPS56128721A JP S56128721 A JPS56128721 A JP S56128721A JP 3030880 A JP3030880 A JP 3030880A JP 3030880 A JP3030880 A JP 3030880A JP S56128721 A JPS56128721 A JP S56128721A
Authority
JP
Japan
Prior art keywords
activity
bronchial asthma
antiallergic agent
compound
antiallergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3030880A
Other languages
Japanese (ja)
Inventor
Shinro Tachibana
Kengo Araki
Takeshi Suzuki
Shizuko Ooya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to JP3030880A priority Critical patent/JPS56128721A/en
Publication of JPS56128721A publication Critical patent/JPS56128721A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PURPOSE: An antiallergic agent that contains a specific basic polypeptide, thus being especially useful as a remedy for bronchial asthma.
CONSTITUTION: The objective antiallergic agent contains a polypetide of the formula, Vasoactive, Intestinal polypeptide (abbreviated to VIP hereinafter) as an active principle. The compound has been isolated from the inside of alimentary tract mucosas and known to have activities of increasing bloodstreams and lowering blood pressures. And now, it has been found to have antiallergic activity. Especially, the compound of the formula has an activity of prohibiting the elimination of chemical mediaton, thus it is useful for treatment and prevention against various kinds of allergoses, e.g., allergic rhinitis, bronchial asthma, or hay fever. Further, it has bronchodilation activity, too, thus being most effectively used for bronchial asthma and allergic asthma. Side-effects also are reduced.
COPYRIGHT: (C)1981,JPO&Japio
JP3030880A 1980-03-12 1980-03-12 Antiallergic agent Pending JPS56128721A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3030880A JPS56128721A (en) 1980-03-12 1980-03-12 Antiallergic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3030880A JPS56128721A (en) 1980-03-12 1980-03-12 Antiallergic agent

Publications (1)

Publication Number Publication Date
JPS56128721A true JPS56128721A (en) 1981-10-08

Family

ID=12300137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3030880A Pending JPS56128721A (en) 1980-03-12 1980-03-12 Antiallergic agent

Country Status (1)

Country Link
JP (1) JPS56128721A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6434923A (en) * 1987-04-30 1989-02-06 Cooper Lab Aerosolization of proteinaceous remedy
US5376637A (en) * 1991-04-22 1994-12-27 Sanwa Kagaku Kenkyusho Co., Ltd. Pharmaceutical preparation containing vasoactive intestinal polypeptide or its analogue
US5428015A (en) * 1990-06-26 1995-06-27 Sana Kagaku Kenkyusho Co., Ltd. Vasoactive intestinal polypeptide analogues and use thereof
WO2004089407A3 (en) * 2003-03-31 2005-01-20 Brigham & Womens Hospital Zwitterionic immunomodulators for the treatment of asthma and allergy
US8008276B2 (en) 2000-12-05 2011-08-30 The Brigham And Women's Hospital, Inc. Use of zwitterionic polysaccharides for the specific modulation of immune processes
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
US10772918B2 (en) 2013-05-10 2020-09-15 California Institute Of Technology Probiotic prevention and treatment of colon cancer
US10857177B2 (en) 2015-08-19 2020-12-08 President And Fellows Of Harvard College Lipidated PSA compositions and methods
US11103566B2 (en) 2010-05-20 2021-08-31 California Institute Of Technology Antigen specific Tregs and related compositions, methods and systems
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
US11419887B2 (en) 2010-04-07 2022-08-23 California Institute Of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US11622973B2 (en) 2007-11-09 2023-04-11 California Institute Of Technology Immunomodulating compounds and related compositions and methods

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618786A (en) * 1987-04-30 1997-04-08 Cooper Laboratories, Inc. Aerosolization of protein therapeutic agent
JPS6434923A (en) * 1987-04-30 1989-02-06 Cooper Lab Aerosolization of proteinaceous remedy
US5428015A (en) * 1990-06-26 1995-06-27 Sana Kagaku Kenkyusho Co., Ltd. Vasoactive intestinal polypeptide analogues and use thereof
US5376637A (en) * 1991-04-22 1994-12-27 Sanwa Kagaku Kenkyusho Co., Ltd. Pharmaceutical preparation containing vasoactive intestinal polypeptide or its analogue
US8008276B2 (en) 2000-12-05 2011-08-30 The Brigham And Women's Hospital, Inc. Use of zwitterionic polysaccharides for the specific modulation of immune processes
US9265790B2 (en) 2003-03-31 2016-02-23 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
AU2004227852B2 (en) * 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2004089407A3 (en) * 2003-03-31 2005-01-20 Brigham & Womens Hospital Zwitterionic immunomodulators for the treatment of asthma and allergy
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
US11622973B2 (en) 2007-11-09 2023-04-11 California Institute Of Technology Immunomodulating compounds and related compositions and methods
US11419887B2 (en) 2010-04-07 2022-08-23 California Institute Of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US11103566B2 (en) 2010-05-20 2021-08-31 California Institute Of Technology Antigen specific Tregs and related compositions, methods and systems
US10772918B2 (en) 2013-05-10 2020-09-15 California Institute Of Technology Probiotic prevention and treatment of colon cancer
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
US10857177B2 (en) 2015-08-19 2020-12-08 President And Fellows Of Harvard College Lipidated PSA compositions and methods
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use

Similar Documents

Publication Publication Date Title
JPS56128721A (en) Antiallergic agent
CA2094137A1 (en) Novel hydroxamic acid and n-hydroxyurea derivatives and their use
JPS56150014A (en) Antiallergic agent
FR2430939B1 (en)
FI854926A0 (en) FREEZING FOR PHARMACOLOGICAL ACTIVE PYRROLOBENSIMIDAZOLER.
JPS567716A (en) Preventive and remedy for cerebral angiospasm
EP0136569A3 (en) Isoflavone derivatives, their production and use
WO2002039999B1 (en) Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
PT75460A (en) 2-<2'-hydroxy-3'-(1,1-dimethylpropylamino)-propoxy>-beta-phenylpropiophenone its acid addition salts process for its preparation and pharmaceutical compositions
SE8500996D0 (en) METHOD OF TREATMENT
JPS56131518A (en) Antiallergic agent
JPS56142213A (en) Pharmacuetical blend for treating parkinsonism syndrome
JPS5721312A (en) Breathable ointment
JPS57112331A (en) Medical composition of ganoderma lucidum component
JPS5585526A (en) Remedy for allergic disease
JPS5742620A (en) Novel antiulcer agent
JPS5795908A (en) Antiallergic agent
AU557772B2 (en) I-furyl-3,4-dihydroisoquinolines
JPS57120519A (en) Preventing agent and remedy for disease caused by srs-a
JPS5780315A (en) Absorption promotor for accelerating rectum absorption, base comprising it, and pharmaceutical preparation to be medicated to rectum
EP0041298A3 (en) Composition for inhibiting or preventing the development of suckers in tobacco plants
JPS57126418A (en) Antiallergic agent
JPS57193428A (en) 2-acyl-6-aminophenol derivative, its preparation, and remedy for diseases caused by leucotriene containing the same
FR2474863B1 (en)
GR850995B (en)